Clinical momentum HypnoVR has a strong clinical credibility with 15 studies demonstrating pain and anxiety reduction, postoperative length of stay impact, and reduced morphine use, suggesting to potential buyers that the solution is evidence-backed and hospital-ready for anesthesia, surgery, and dental procedures.

Strategic partnerships Active distribution through UniHA, UGAP, CAHPP, Helpevia, Vivalto Santé, and Elsan indicates established procurement channels and credibility with major French healthcare groups, presenting a ready path for expansion in similar hospital networks or regional group purchasing organizations.

Acquisition signals Recent acquisition of Oncomfort SA reinforces HypnoVR’s leadership in digital sedation and VR-based therapy, signaling an expanding product ecosystem and potential cross-sell opportunities to existing Oncomfort customers and tech-adjacent buyers.

Financial runway With funding of about €5 million and ongoing SaaS-like or device-based offering, HypnoVR presents a lean cost structure and growth potential attractive to investors and enterprise buyers seeking innovative non-pharmacologic pain management solutions.

Industry fit Target markets include hospitals and clinics focusing on anesthesia, surgery, and dental procedures, where HypnoVR’s multisensory VR hypnosis can differentiate care pathways, reduce opioid use, and shorten stays—a compelling value prop for procurement teams aiming to modernize pain management.